Overview

OmegAD (Omega-3 and Alzheimer's Disease)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients
Phase:
N/A
Details
Lead Sponsor:
Karolinska University Hospital